Concordia Healthcare Corp (TSE:CXR)‘s stock had its “outperform” rating reiterated by Royal Bank Of Canada in a research note issued to investors on Tuesday, StockTargetPrices.com reports. They currently have a C$18.50 target price on the stock. Royal Bank Of Canada’s target price would indicate a potential upside of 226.28% from the stock’s previous close.
Several other research analysts have also weighed in on the stock. Goldman Sachs Group Inc. decreased their price objective on shares of Concordia Healthcare Corp from C$34.00 to C$17.00 in a report on Monday, August 15th. TD Securities decreased their price objective on shares of Concordia Healthcare Corp from C$45.00 to C$37.00 and set a “buy” rating for the company in a report on Tuesday, June 28th. Finally, CIBC lowered shares of Concordia Healthcare Corp from a “sector perform” rating to an “underperform” rating in a report on Monday, August 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of C$27.38.
Shares of Concordia Healthcare Corp (TSE:CXR) opened at 5.67 on Tuesday. Concordia Healthcare Corp has a 12 month low of $5.64 and a 12 month high of $58.75. The company has a 50-day moving average of $8.24 and a 200-day moving average of $24.40. The stock’s market capitalization is $289.27 million.
About Concordia Healthcare Corp